Kura Oncology(KURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KURA Kura Oncology

Post-Mkt 01-16 17:26:49 EST

8.46

-0.45

-5.05%

盘后8.40

-0.06-0.71%

17:16 EST

High9.06	Low8.44	Vol2.30M
Open9.02	D1 Closing8.91	Amplitude6.96%
Mkt Cap736.17M	Tradable Cap541.32M	Total Shares87.02M
T/O19.81M	T/O Rate3.60%	Tradable Shares63.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KURA","market":"US","secType":"STK","nameCN":"Kura Oncology","latestPrice":8.46,"timestamp":1768597200000,"preClose":8.91,"halted":0,"volume":2300610,"hourTrading":{"tag":"盘后","latestPrice":8.4,"preClose":8.46,"latestTime":"17:16 EST","volume":35284,"amount":298513.895596,"timestamp":1768601793702},"delay":0,"floatShares":63985582,"shares":87017518,"eps":-2.480148,"marketStatus":"Post-Mkt","change":-0.45,"latestTime":"01-16 17:26:49 EST","open":9.02,"high":9.0599,"low":8.44,"amount":19813751.708205,"amplitude":0.069574,"askPrice":9.63,"askSize":100,"bidPrice":8.37,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.480148,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1768611600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1446699600000,"exchange":"NASDAQ","adjPreClose":8.91,"preHourTrading":{"tag":"盘前","latestPrice":9.01,"preClose":8.91,"latestTime":"09:29 EST","volume":4884,"amount":44135.63352,"timestamp":1768573799999},"postHourTrading":{"tag":"盘后","latestPrice":8.4,"preClose":8.46,"latestTime":"17:16 EST","volume":35284,"amount":298513.895596,"timestamp":1768601793702},"volumeRatio":1.834888,"impliedVol":0.5279,"impliedVolPercentile":0.2789},"requestUrl":"/m/hq/s/KURA","defaultTab":"news","newsList":[{"id":"2603809246","title":"Kura Oncology price target lowered to $20 from $25 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2603809246","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603809246?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:16","pubTimestamp":1768313767,"startTime":"0","endTime":"0","summary":"Leerink lowered the firm’s price target on Kura Oncology (KURA) to $20 from $25 and keeps an Outperform rating on the shares ahead of the company’s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kura-oncology-price-target-lowered-to-20-from-25-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kura-oncology-price-target-lowered-to-20-from-25-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KURA"],"gpt_icon":0},{"id":"2603681838","title":"Kura Oncology Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681838","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681838?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:40","pubTimestamp":1768308000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 07:40 ET (12:40 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA"],"gpt_icon":0},{"id":"2603968570","title":"Kura Oncology Inc : Leerink Partners Cuts Target Price to $20 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2603968570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603968570?lang=en_us&edition=fundamental","pubTime":"2026-01-13 19:57","pubTimestamp":1768305440,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE0UV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","KURA"],"gpt_icon":0},{"id":"2603507572","title":"Barclays Sticks to Its Buy Rating for Kura Oncology (KURA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603507572","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603507572?lang=en_us&edition=fundamental","pubTime":"2026-01-13 17:56","pubTimestamp":1768298173,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on Kura Oncology, with a price target of $28.00. According to TipRan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-buy-rating-for-kura-oncology-kura-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-buy-rating-for-kura-oncology-kura-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KURA"],"gpt_icon":0},{"id":"2603528954","title":"Kura Oncology Unveils Precision Medicine Advances and Pipeline Expansion in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2603528954","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603528954?lang=en_us&edition=fundamental","pubTime":"2026-01-13 02:41","pubTimestamp":1768243315,"startTime":"0","endTime":"0","summary":"Kura Oncology Inc. has highlighted key developments in its latest corporate presentation. The company announced the approval of KOMZIFTI  for the treatment of adult patients with relapsed or refractory NPM1-mutated acute myeloid leukemia . Kura retains leadership and key strategic rights to ziftomenib in the U.S., while engaging in a 50/50 co-development and co-promotion partnership, with Kura booking all U.S. sales and leading global development. The company is pursuing a comprehensive clinical development strategy for ziftomenib, including combination therapies and studies targeting up to 50% of AML patients. Additional pipeline advancements include the development of KO-7246, a next-generation menin inhibitor for diabetes and cardiometabolic diseases, and ongoing research into darlifarnib combination regimens in solid tumors such as RCC and KRASG12C-mutant cancers. Kura also plans to expand its pipeline with assets targeting solid tumors, including ER+ driven tumors. You can access ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL21klKd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4505","BK4139"],"gpt_icon":0},{"id":"2602256784","title":"Analysts Offer Insights on Healthcare Companies: Cerus (CERS) and Kura Oncology (KURA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602256784","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602256784?lang=en_us&edition=fundamental","pubTime":"2026-01-12 11:10","pubTimestamp":1768187416,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cerus (CERS – Research Report) and Kura Oncology (KU...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cerus-cers-and-kura-oncology-kura-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cerus-cers-and-kura-oncology-kura-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","KURA","BK4137","BK4139","LU0029874061.USD","CERS","KUmain","XLV","BK4588","BK4581","HCSG","BK4505","BK4198","BK4585","XBI","LU0128526141.USD"],"gpt_icon":0},{"id":"2602682765","title":"Kura Oncology projects $45M–$55M in non-cash collaboration revenue for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602682765","media":"Reuters","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602682765?lang=en_us&edition=fundamental","pubTime":"2026-01-12 06:00","pubTimestamp":1768168838,"startTime":"0","endTime":"0","summary":"Kura Oncology Inc. announced its financial guidance for 2026, projecting non-cash collaboration revenue recognition in the range of $45 million to $55 million for the year. For the fourth quarter of 2025, the company reported preliminary KOMZIFTI net product revenue of $2.1 million during the initial five weeks of commercial availability. Additionally, Kura recorded milestone payments totaling $195 million from its collaboration agreement with Kyowa Kirin in the fourth quarter of 2025. As of December 31, 2025, the company reported $667.3 million in cash, cash equivalents, and short-term investments. This strong financial position, combined with anticipated collaboration payments and product revenue, is expected to support the ziftomenib AML program through topline results in a front-line Phase 3 trial in newly diagnosed AML.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nNDLbC9YNb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4139","BK4585","SG9999014039.USD","SG9999014013.SGD","LU2210150020.SGD","SG9999014021.USD","BK4588","LU2210149790.SGD","BK4505","IE00BKPKM429.USD","IE00B3QW5Z07.USD","NDAQ","BK4112","KURA","LU0314104364.USD","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014005.SGD"],"gpt_icon":0},{"id":"2602563399","title":"Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602563399","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602563399?lang=en_us&edition=fundamental","pubTime":"2026-01-12 06:00","pubTimestamp":1768168800,"startTime":"0","endTime":"0","summary":"– Launched KOMZIFTI (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML –  – $2.1 million KOMZIFTI net product revenue for the period from first","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/11/3216496/35186/en/Kura-Oncology-Highlights-Recent-Accomplishments-Preliminary-KOMZIFTI-Revenue-and-Anticipated-2026-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA"],"gpt_icon":0},{"id":"2601024886","title":"Kura Oncology Grants Stock Options to New Employees Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2601024886","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601024886?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:30","pubTimestamp":1767616223,"startTime":"0","endTime":"0","summary":"Kura Oncology Inc. has granted nonstatutory stock options to purchase 49,750 shares of common stock to three new employees under its 2023 Inducement Option Plan. Each stock option has an exercise price of $10.34 per share, matching the closing price of the company's common stock on January 2, 2026. The options will vest over four years, with 25% vesting on the one-year anniversary of the vesting commencement date and the remaining shares vesting monthly over the following 36 months, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely responsible for the information conta","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL5fQX66:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014021.USD","KURA","IE00B64PRP62.GBP","LU2210150020.SGD","BK4505","LU2210149790.SGD","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014005.SGD","BK4112","LU0314104364.USD","SG9999014013.SGD","LU2095319765.USD","NDAQ"],"gpt_icon":0},{"id":"2601894438","title":"Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601894438","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601894438?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:30","pubTimestamp":1767616200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan.  05, 2026  (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatme","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/05/3212649/35186/en/Kura-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KURA","BK4505"],"gpt_icon":0},{"id":"2592190378","title":"Kura Oncology Chief Scientific Officer Francis Burrows Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592190378","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592190378?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:30","pubTimestamp":1766179833,"startTime":"0","endTime":"0","summary":"Francis Burrows, Chief Scientific Officer of Kura Oncology Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL64V6N9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kura Oncology Chief Scientific Officer Francis Burrows Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4505","BK4139"],"gpt_icon":0},{"id":"2590558168","title":"Kura Oncology Director Faheem Hasnain Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590558168","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590558168?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400739,"startTime":"0","endTime":"0","summary":"Faheem Hasnain, Director at Kura Oncology Inc., has reported a disposal of common shares of the company, according to a recent SEC filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL4w2j1z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kura Oncology Director Faheem Hasnain Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","KURA"],"gpt_icon":0},{"id":"2589544543","title":"Kura Oncology Inc - Registrational Trials of Ziftomenib in Front-Line Aml Ongoing","url":"https://stock-news.laohu8.com/highlight/detail?id=2589544543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589544543?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:40","pubTimestamp":1765208405,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE10Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","KURA"],"gpt_icon":0},{"id":"2589354451","title":"Kura Oncology Inc - Triplet Combination for Komzifti With Venetoclax and Azacitidine  Well Tolerated in Newly Diagnosed and R/R Settings","url":"https://stock-news.laohu8.com/highlight/detail?id=2589354451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589354451?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:40","pubTimestamp":1765208405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE10Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","KURA"],"gpt_icon":0},{"id":"2589735464","title":"Kura Oncology Reports Positive Data for KOMZIFTI Triplet Combo in AML Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589735464","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589735464?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:30","pubTimestamp":1765207814,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL8tr06F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","NDAQ","BK4505","LU2095319765.USD","BK4585","IE00BKPKM429.USD","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014039.USD","BK4588","IE00B3QW5Z07.USD","LU2210149790.SGD","KURA","LU0314104364.USD","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4112","BK4139"],"gpt_icon":0},{"id":"2589435418","title":"Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2589435418","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589435418?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:30","pubTimestamp":1765207800,"startTime":"0","endTime":"0","summary":"– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and over","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201703/35186/en/Kura-Oncology-and-Kyowa-Kirin-Report-Combination-Data-for-KOMZIFTI-Ziftomenib-with-Venetoclax-and-Azacitidine-in-Newly-Diagnosed-and-Relapsed-Refractory-AML.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","NGS","BK4505","BK4139","BK4179"],"gpt_icon":0},{"id":"2588418270","title":"Kura Oncology Hosts Virtual Investor Event on Ziftomenib Triplet Data in Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2588418270","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588418270?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:32","pubTimestamp":1764768730,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL8pxhl1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","BK4588","KURA","IE00B3QW5Z07.USD","BK4585","IE00B64PRP62.GBP","BK4505","LU2095319765.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4112","LU2210150020.SGD","BK4139"],"gpt_icon":0},{"id":"2588053285","title":"Kura Oncology Secures $135 Million Milestone Payment from Kyowa Kirin","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053285","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053285?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:02","pubTimestamp":1764680568,"startTime":"0","endTime":"0","summary":"Kura Oncology Inc. announced the completion of the first U.S. commercial sale of KOMZIFTI , following its FDA approval on November 13, 2025. This sale has triggered a $135 million milestone payment to Kura under its collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc. Kura expects to receive the payment before the end of the year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on December 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL5sknTM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4505","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","NDAQ","KURA","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2588905349","title":"First U.S. Commercial Sale of Komzifti™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement With Kyowa Kirin","url":"https://stock-news.laohu8.com/highlight/detail?id=2588905349","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588905349?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:02","pubTimestamp":1764680520,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA86G3JH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","KURA"],"gpt_icon":0},{"id":"2586289851","title":"Positive Outlook on Kura Oncology: Komzii’s Approval and Safety Profile Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2586289851","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586289851?lang=en_us&edition=fundamental","pubTime":"2025-11-26 09:45","pubTimestamp":1764121527,"startTime":"0","endTime":"0","summary":"Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Kura Oncology and keeping the price target at $28.00. Charles Zhu has given his...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-on-kura-oncology-komziis-approval-and-safety-profile-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-on-kura-oncology-komziis-approval-and-safety-profile-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KURA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kuraoncology.com","stockEarnings":[{"period":"1week","weight":-0.067},{"period":"1month","weight":-0.1618},{"period":"3month","weight":-0.0945},{"period":"6month","weight":0.4009},{"period":"1year","weight":0.2307},{"period":"ytd","weight":-0.1424}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.103},{"period":"1year","weight":0.1678},{"period":"ytd","weight":0.0151}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.009221},{"month":2,"riseRate":0.5,"avgChangeRate":0.027496},{"month":3,"riseRate":0.6,"avgChangeRate":-0.029894},{"month":4,"riseRate":0.2,"avgChangeRate":-0.031764},{"month":5,"riseRate":0.5,"avgChangeRate":0.015121},{"month":6,"riseRate":0.5,"avgChangeRate":0.037607},{"month":7,"riseRate":0.5,"avgChangeRate":0.037366},{"month":8,"riseRate":0.5,"avgChangeRate":0.066679},{"month":9,"riseRate":0.5,"avgChangeRate":0.12103},{"month":10,"riseRate":0.3,"avgChangeRate":-0.077132},{"month":11,"riseRate":0.8,"avgChangeRate":0.052179},{"month":12,"riseRate":0.454545,"avgChangeRate":0.00367}],"exchange":"NASDAQ","name":"Kura Oncology","nameEN":"Kura Oncology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kura Oncology(KURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kura Oncology(KURA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kura Oncology,KURA,Kura Oncology股票,Kura Oncology股票老虎,Kura Oncology股票老虎国际,Kura Oncology行情,Kura Oncology股票行情,Kura Oncology股价,Kura Oncology股市,Kura Oncology股票价格,Kura Oncology股票交易,Kura Oncology股票购买,Kura Oncology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kura Oncology(KURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kura Oncology(KURA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction